Please ensure Javascript is enabled for purposes of website accessibility

This Is Why Moderna Is a Great Stock to Buy Right Now

By Adria Cimino - Apr 9, 2021 at 6:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Like Moderna's vaccine revenue so far? The future's even brighter.

Moderna (MRNA -0.37%) has accomplished a lot in the past year. It made a name for itself in the world's most watched space: coronavirus prevention. It launched its first product: a coronavirus vaccine. And last year, it saw its market value and stock price soar -- by more than 500% and 400%, respectively. Those who've been invested in Moderna since Day 1 clearly hit the jackpot.

Some investors may be wondering if it's time to forget about Moderna and try to find tomorrow's new coronavirus star. It's always a good idea to look for promising newcomers.

But that doesn't mean it's time to forget about today's strong players, and that's exactly what Moderna has become. Even better, the Moderna growth story is far from over. In fact, it's just beginning. And that's why now is a great time to invest in this dynamic coronavirus stock.

An investor cheers outside an office building.

Image source: Getty Images.

Coronavirus vaccine titans

Moderna and rival Pfizer have become coronavirus vaccine titans as they hold the greatest share of the U.S. vaccine market. Moderna has fully vaccinated more than 27 million people there. That compares to 32 million for Pfizer. It's important to remember that Pfizer got a head start: The U.S. Food and Drug Administration (FDA) authorized its vaccine about a week ahead of Moderna's.

It's fair to say that both players are on equal footing, and that might continue. They both are at about the same stage of clinical testing of their vaccines in kids and teens and both are exploring boosters to better handle strains of concern. But that's OK. They can share the U.S. market and carve out share in the global market among other rivals -- and still end up with billions in revenue.

Let's take a closer look at revenue. Moderna posted more than $199 million in coronavirus vaccine revenue in the fourth quarter -- and the vaccine was only commercialized for two weeks during that period. The company expects to generate at least $18.4 billion this year according to the advance purchase agreements it has signed so far. And earnings-per-share (EPS) estimates for the full year have been rising since the start of the year. The estimate now is at $22.51.

MRNA EPS Estimates for Current Fiscal Year Chart

MRNA EPS Estimates for Current Fiscal Year data by YCharts.

This is a huge deal for a company that didn't have commercialized products (and therefore, product revenue) last year. The next question is: Will this blockbuster level of revenue be recurrent?

Recently, a study showed that Moderna's vaccine produces immunity for at least six months. Earlier in the year, CEO Stephane Bancel said antibody decay indicates Moderna vaccine protection may even last a couple of years.

So we might imagine a vaccination once a year or once every two years. And with the growth of variants of concern, it's very possible an annual booster will become part of the mix. All of this means we probably could expect billions of dollars in coronavirus vaccine -- or booster -- revenue annually or spread across two years.

The whole pipeline

I have even more good news. It's unlikely Moderna will rely uniquely on the coronavirus vaccine over the long term. This program has offered its entire pipeline a boost because it showed Moderna's mRNA technology works.

Moderna's closest-to-market pipeline candidate is a cytomegalovirus (CMV) vaccine. CMV is a common virus that's most problematic for those who are pregnant or have a weakened immune system. Moderna plans to launch a phase 3 trial this year.

The company also has about 20 other candidates in the pipeline. That includes two cancer vaccines and a therapeutic for a heart condition, and they're in phase 2 trials.

Moderna shares have climbed more than 300% over the past year. But at today's level, they're trading at only 5.9 times forward earnings estimates. That's down from more than eight earlier this year. And that was already pretty low.

MRNA PE Ratio (Forward) Chart

MRNA PE Ratio (Forward) data by YCharts.

Considering future revenue -- from the coronavirus vaccine and possibly other products -- Moderna shares aren't expensive today. I would buy this biotech stock right now for potential earnings and share-price growth years down the road.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc.. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$171.18 (-0.37%) $0.63
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$50.11 (3.77%) $1.82

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.